Literature DB >> 12006790

Protective effect of a novel, potent inhibitor of poly(adenosine 5'-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis.

Roy D Goldfarb1, Anita Marton, Eva Szabó, László Virág, Andrew L Salzman, Dana Glock, Imran Akhter, Robert McCarthy, Joseph E Parrillo, Csaba Szabó.   

Abstract

OBJECTIVE: To determine whether activation of the nuclear enzyme poly(adenosine 5'-diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot.
DESIGN: Prospective, random animal study.
SETTING: Research laboratory at Rush Presbyterian St. Luke's Medical Center.
SUBJECTS: Twenty pigs were chronically instrumented with intracardiac transducers to measure left ventricular pressure, sonomicrometer crystals in the left ventricle to measure short axis diameter, an ultrasonic flow meter to measure cardiac output, and catheters in the pulmonary artery and aorta to measure blood pressures and collect samples.
INTERVENTIONS: By using a randomized study design, we administered either the novel potent PARS inhibitor PJ34 (10 mg/kg for 1 hr, 2 mg x kg(-1) x hr(-1) for 96 hrs) or vehicle to pigs immediately before intraperitoneal implantation of Escherichia coli 0111.B4 (2.3 +/- 0.1 x 10(10) colony-forming units/kg)-laden fibrin clots to produce peritonitis and bacteremia.
MEASUREMENTS AND MAIN RESULTS: In vehicle-treated pigs, 12% survival was recorded at 24 hrs, whereas 83% and 66% survival was recorded in the PJ34-treated animals at 24 and 96 hrs, respectively (p <.05). PJ34 treatment attenuated bacteremia-induced increases in systemic and pulmonary vascular resistances. In controls, peritonitis induced rapid increase in plasma tumor necrosis factor-alpha. PJ34 treatment significantly attenuated this cytokine response. The formation of peroxynitrite and the activation of PARS were confirmed in hearts and lungs of the septic pigs by the immunohistochemical detection of nitrotyrosine and poly(ADP-ribose), respectively. Inhibition of PARS with PJ34 abolished poly(ADP-ribose) formation in septic animals.
CONCLUSIONS: Treatment with a potent PARS inhibitor improved survival and cardiovascular status and attenuated an important mediator component of the inflammatory response in a lethal porcine model of sepsis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006790     DOI: 10.1097/00003246-200205000-00004

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  21 in total

1.  Inhibition of poly(adenosine diphosphate-ribose) polymerase attenuates ventilator-induced lung injury.

Authors:  Rosanna Vaschetto; Jan W Kuiper; Shyh Ren Chiang; Jack J Haitsma; Jonathan W Juco; Stefan Uhlig; Frans B Plötz; Francesco Della Corte; Haibo Zhang; Arthur S Slutsky
Journal:  Anesthesiology       Date:  2008-02       Impact factor: 7.892

2.  Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway.

Authors:  Rosanna Vaschetto; Jan W Kuiper; René J P Musters; Etto C Eringa; Francesco Della Corte; Kanneganti Murthy; A B Johan Groeneveld; Frans B Plötz
Journal:  Crit Care       Date:  2010-03-26       Impact factor: 9.097

Review 3.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

4.  PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.

Authors:  Kunal Kapoor; Esha Singla; Bijayani Sahu; Amarjit S Naura
Journal:  Mol Cell Biochem       Date:  2014-11-18       Impact factor: 3.396

Review 5.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

6.  Upregulation of Salmonella-induced IL-6 production in Caco-2 cells by PJ-34, PARP-1 inhibitor: involvement of PI3K, p38 MAPK, ERK, JNK, and NF-kappaB.

Authors:  Fu-Chen Huang
Journal:  Mediators Inflamm       Date:  2010-02-24       Impact factor: 4.711

7.  Nicotinamide increases systemic vascular resistance in ovine endotoxemia.

Authors:  Marion Scharte; Jerzy-Roch Nofer; Hugo Van Aken; Rene Waurick; Jörg Meyer; Hans-Georg Bone
Journal:  Intensive Care Med       Date:  2003-05-01       Impact factor: 17.440

Review 8.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

9.  Treatment with insulin inhibits poly(ADP-ribose)polymerase activation in a rat model of endotoxemia.

Authors:  Eszter M Horváth; Rita Benko; Domonkos Gero; Levente Kiss; Csaba Szabó
Journal:  Life Sci       Date:  2007-11-21       Impact factor: 5.037

10.  Effect of fluid resuscitation on mortality and organ function in experimental sepsis models.

Authors:  Sebastian Brandt; Tomas Regueira; Hendrik Bracht; Francesca Porta; Siamak Djafarzadeh; Jukka Takala; José Gorrasi; Erika Borotto; Vladimir Krejci; Luzius B Hiltebrand; Lukas E Bruegger; Guido Beldi; Ludwig Wilkens; Philipp M Lepper; Ulf Kessler; Stephan M Jakob
Journal:  Crit Care       Date:  2009-11-23       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.